198 related articles for article (PubMed ID: 15014552)
1. Clinical and sonographic assessment of the side effects of intracavernous injection of vasoactive substances.
Moemen MN; Hamed HA; Kamel II; Shamloul RM; Ghanem HM
Int J Impot Res; 2004 Apr; 16(2):143-5. PubMed ID: 15014552
[TBL] [Abstract][Full Text] [Related]
2. Intracavernous chlorpromazine versus phentolamine: a double-blind clinical comparative study.
Shamloul R; El-Dakhly M; Ghanem H; Gadallah A; Mokhtar H
J Sex Med; 2004 Nov; 1(3):310-3. PubMed ID: 16422961
[TBL] [Abstract][Full Text] [Related]
3. Prostaglandin E1 with phentolamine for the treatment of erectile dysfunction.
Meinhardt W; de la Fuente RB; Lycklama à Nijeholt AA; Vermeij P; Zwartendijk J
Int J Impot Res; 1996 Mar; 8(1):5-7. PubMed ID: 8735187
[TBL] [Abstract][Full Text] [Related]
4. [Current role of intracavernous therapy in the treatment of erectile dysfunction].
Asuar Aydillo S
Arch Esp Urol; 2002 Jun; 55(5):475-82. PubMed ID: 12174413
[No Abstract] [Full Text] [Related]
5. [Intracavernous pharmacotherapy for treatment and evaluation of impotence].
Vardi Y; Lidgi S; Moskovitz B; Levin RD
Harefuah; 1991 Oct; 121(7-8):223-5. PubMed ID: 1783307
[TBL] [Abstract][Full Text] [Related]
6. [Response to intracavernous administration of 3 different drugs in the same group of patients with erectile dysfunction].
Ribé N; Rajmil O; Bassas L; Jurado C; Pomerol JM
Arch Esp Urol; 2001 May; 54(4):355-9. PubMed ID: 11455770
[TBL] [Abstract][Full Text] [Related]
7. Intracavernous injections for erectile dysfunction in patients with cardiovascular diseases and failure or contraindications for sildenafil citrate.
Israilov S; Niv E; Livne PM; Shmueli J; Engelstein D; Segenreich E; Baniel J
Int J Impot Res; 2002 Feb; 14(1):38-43. PubMed ID: 11896476
[TBL] [Abstract][Full Text] [Related]
8. [Evaluation of 452 patients with erectile dysfunction treated by combinations of vasoactive agents by penile injection].
Segenreich E; Israilov S; Shmueli J; Simon D; Baniel J; Livne P
Harefuah; 1998 May; 134(9):673-8, 750. PubMed ID: 10909609
[TBL] [Abstract][Full Text] [Related]
9. Transurethral alprostadil as therapy for patients who withdrew from or failed prior intracavernous injection therapy.
Engel JD; McVary KT
Urology; 1998 May; 51(5):687-92. PubMed ID: 9610580
[TBL] [Abstract][Full Text] [Related]
10. Comparison of a mixture of papaverine, phentolamine and prostaglandin E1 with other intracavernous injections.
Meinhardt W; Lycklama à Nijeholt AA; Kropman RF; Vermeij P; Zwartendijk J
Eur Urol; 1994; 26(4):319-21. PubMed ID: 7713130
[TBL] [Abstract][Full Text] [Related]
11. Short term use of intracavernous vasoactive drugs in the treatment of persistent psychogenic erectile dysfunction.
Ghanem H; Sherif T; Adbel-Gawad T; Asaad T
Int J Impot Res; 1998 Dec; 10(4):211-4. PubMed ID: 9884916
[TBL] [Abstract][Full Text] [Related]
12. [Intracavernous injection of vasoactive drugs for treating erectile impotence].
Yasumoto R; Asakawa M; Kawashima H; Yoshimura R; Maekawa T; Kashiwara N; Tanaka H; Nishio S
Hinyokika Kiyo; 1988 Feb; 34(2):301-4. PubMed ID: 2454019
[TBL] [Abstract][Full Text] [Related]
13. A prospective randomized study to optimize the dosage of trimix ingredients and compare its efficacy and safety with prostaglandin E1.
Seyam R; Mohamed K; Akhras AA; Rashwan H
Int J Impot Res; 2005; 17(4):346-53. PubMed ID: 15772683
[TBL] [Abstract][Full Text] [Related]
14. [Prospective study of the effectiveness and side effects of intracavernous prostaglandin E1 versus papaverine or papaverine phentolamine in the diagnosis and treatment of erection dysfunction. Review of the literature].
Chandeck Montesa K; Chen Jiménez J; Tamayo JC; Rodríguez Antolín A; Alvarez González E
Actas Urol Esp; 1992 Mar; 16(3):208-16. PubMed ID: 1621545
[TBL] [Abstract][Full Text] [Related]
15. [Long-term results of the treatment with intracavernous injection of vasoactive drugs].
Rodríguez Vela L; Gonzalvo Ibarra A; Gil Martínez P; Benejan Gual J; Cuesta Presedo JM; Ríoja Sanz LA
Arch Esp Urol; 1996 Apr; 49(3):257-69. PubMed ID: 8702347
[TBL] [Abstract][Full Text] [Related]
16. [Percutaneous use of vasoactive drugs in the diagnosis and treatment of erectile impotence].
Pastorini S; Marino G; Cocimano V; Marten Perolino R
Minerva Urol Nefrol; 1992; 44(3):191-3. PubMed ID: 1492270
[TBL] [Abstract][Full Text] [Related]
17. Fibrosis of corpus cavernosum after intracavernous injection of phentolamine/papaverine.
Larsen EH; Gasser TC; Bruskewitz RC
J Urol; 1987 Feb; 137(2):292-3. PubMed ID: 3806824
[TBL] [Abstract][Full Text] [Related]
18. Intracavernous self-injection pharmacotherapy program: analysis of results and complications.
Valdevenito R; Melman A
Int J Impot Res; 1994 Jun; 6(2):81-91. PubMed ID: 7951702
[TBL] [Abstract][Full Text] [Related]
19. [3 years' experience with intracavernous auto-injection therapy].
Weiske WH
Urologe A; 1989 Sep; 28(5):253-6. PubMed ID: 2815435
[TBL] [Abstract][Full Text] [Related]
20. [Clinical evaluation of intracavernous self-injection of vasoactive drugs for impotence: a long-term follow-up observation].
Hayashi S; Iwai Y; Yasumoto R; Matsuda J; Kawano M; Omachi T; Kono T; Yamamoto S; Sakakura T; Minami H
Hinyokika Kiyo; 1994 Jan; 40(1):37-41. PubMed ID: 7509119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
